Coagulopathy in two patients with cystic fibrosis treated with ciprofloxacin

Journal of Cystic Fibrosis

Volumn 6, Issue 3, 2007, Pages 209-211

  Moore, Gillian C ^a   Redfern, Jan ^a   Shiach, Caroline R ^a   Webb, Kevin ^a   Jones, Andrew M ^a  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

APTT; Ciprofloxacin; Coagulopathy; Cystic fibrosis; INR

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; CREATININE; ENOXAPARIN; PARACETAMOL; RIFAMPICIN; TOBRAMYCIN; UREA; WARFARIN;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; CASE REPORT; CYSTIC FIBROSIS; DEEP VEIN THROMBOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GRAM NEGATIVE INFECTION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INTERNAL JUGULAR VEIN; INTERNATIONAL NORMALIZED RATIO; INTERSTITIAL NEPHRITIS; INTESTINE OBSTRUCTION; NEBULIZER; OUTPATIENT; PARTIAL THROMBOPLASTIN TIME; PSEUDOMONAS AERUGINOSA; SPIROMETRY; SYMPTOM; VASCULAR ACCESS; VEIN THROMBOSIS; VOMITING;

ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; BLOOD COAGULATION DISORDERS; CIPROFLOXACIN; CYSTIC FIBROSIS; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PSEUDOMONAS INFECTIONS;

EID: 34247108957     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2006.08.002     Document Type: Article

References (13)

1. Taccetti G., Campana S., Fastini F., Mascherini M., and Doring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 26 3 (Sep 2005) 458-461
2. Canton R., Cobos N., de Gracia J., Baquero F., Honorato J., Gartner S., et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 11 9 (Sep 2005) 690-703
3. Ellis R.J., Mayo M.S., and Bodensteiner D.M. Ciprofloxacin-warfarin coagulopathy: a case series. Am J Hematol 63 1 (Jan 2000) 28-31
4. Bianco T.M., Bussey H.I., Farnett L.E., Linn W.D., Roush M.K., and Yong Y.W. Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation. Pharmacotherapy 12 6 (1992) 435-439
5. Fuhr U., Anders E.M., Mahr G., Sorgel F., and Staib A.H. Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother 36 5 (May 1992) 942-948
6. http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE and nodeId=742 Accessed 05/02/06.
7. Miesbach W. Rituximab in the treatment of factor VIII inhibitor possibly caused by Ciprofloxacin. Thromb Haemost 93 5 (May 2005) 1001-1003
8. Castaman G., Lattuada A., Mannucci P.M., and Rodeghiero F. Characterization of two cases of acquired transitory von Willebrand syndrome with ciprofloxacin: evidence for heightened proteolysis of von Willebrand factor. Am J Hematol 49 1 (May 1995) 83-86
9. Pilmore H.L., and Walker R.J. Prolonged bleeding time during ciprofloxacin therapy. J Clin Pharm Ther 20 (1995) 45-46
10. Miesbach W., Voigt J., Peetz D., and Scharrer I. Massive bleeding symptoms in two patients with factor V inhibitor and antiphospholipid antibodies after treatment with ciprofloxacin. Med Klin (Munich) 98 6 (Jun 15 2003) 339-343
11. Rey E., Treluyer G.M., and Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet 35 4 (Oct 1998) 313-329
12. Wilson D.C., Rashid M., Durie P.R., Tsang A., Kalnins D., Andrew M., et al. Treatment of vitamin K deficiency in cystic fibrosis: effectiveness of a daily fat-soluble vitamin combination. J Pediatr 138 6 (Jun 2001) 851-855
13. Flume P.A., Yankaskas J.R., Ebeling M., Hulsey T., and Clark L.L. Massive hemoptysis in cystic fibrosis. Chest 128 2 (Aug 2005) 729-738